Kate O’Neill

Community Spotlight

LuMind IDSC names new Director of Community Programs

Following a five-month, national search, LuMind IDSC Down Syndrome Foundation announced the appointment of Christina…

Kate O’NeillSeptember 21, 2023

Community Spotlight Research News Research Spotlight

Boston Globe OpEd People with Down Syndrome Now Left Out of Treatment

LuMind IDSC and The Arc of Northeast collaborated on an OpEd that was recently published…

Kate O’NeillSeptember 18, 2023

Community Spotlight Research News

Key updates on Down syndrome community access to new Alzheimer’s drugs

Five takeaways for the Down syndrome community: Updates on accessing the new Alzheimer’s drugsLuMind IDSC…

Kate O’NeillJuly 7, 2023

Research News Research Spotlight

LuMind IDSC statement on FDA approval of Leqembi

LuMind IDSC issues statement following FDA full approval of Leqembi™ to treat early-stage Alzheimer’s disease …

Kate O’NeillJuly 7, 2023

Community Spotlight

Meet the Black Down Syndrome Association

by guest contributor, Crystal Lotterberry, co-founder of the Black Down Syndrome Association About the Black…

Kate O’NeillJuly 7, 2023

Press Release Research News

MapHabit Study: Assistive Technology Has Positive Outcomes for Children with Down Syndrome

Study Finds Assistive Technology Has Positive Outcomes for Children with Down Syndrome and Their Caregivers …

Kate O’NeillJune 2, 2023

Research News Press Release Research Spotlight

Expert panel addresses inequitable access to Alzheimer’s drugs for adults with Down syndrome

Seeking to rectify existing federal and state policies which prevent people with intellectual disabilities from…

Kate O’NeillJune 1, 2023

Community Spotlight

LuMind IDSC joins Advocacy Day on Capitol Hill

In April, leaders from LuMind IDSC joined with 350 self-advocates, caregivers, and professionals to meet…

Kate O’NeillMay 12, 2023

Research News Research Spotlight

LuMind IDSC Statement re: Donanemab Phase 3 Results

Pharmaceutical company Eli Lilly today announced results of a phase III clinical trial that proves…

Kate O’NeillMay 3, 2023

Sleep Apnea and Down Syndrome, LuMind IDSC Foundation

Research Spotlight Research News Sleep Apnea

Important progress in the treatment of sleep apnea and Down syndrome

At the end of March, the US Food & Drug Administration approved Inspire’s Hypoglossal Nerve…

Kate O’NeillMarch 29, 2023

LuMind IDSC names new Director of Community Programs

Boston Globe OpEd People with Down Syndrome Now Left Out of Treatment

Key updates on Down syndrome community access to new Alzheimer’s drugs

LuMind IDSC statement on FDA approval of Leqembi

Meet the Black Down Syndrome Association

MapHabit Study: Assistive Technology Has Positive Outcomes for Children with Down Syndrome

Expert panel addresses inequitable access to Alzheimer’s drugs for adults with Down syndrome

LuMind IDSC joins Advocacy Day on Capitol Hill

LuMind IDSC Statement re: Donanemab Phase 3 Results

Important progress in the treatment of sleep apnea and Down syndrome

Recent Posts

CONTACT LUMIND IDSC

QUICK LINKS

NEED MORE INFORMATION?